Crohn's Disease
Crohn's disease is a chronic inflammatory bowel disease (IBD) that causes inflammation of the digestive tract. It can affect any part of the GI tract from mouth to anus but most commonly involves the end of the small intestine (ileum) and the beginning of the colon. The inflammation often spreads deep into affected tissues.
Prevalence
Crohn's disease affects approximately 780,000 Americans. The incidence has been increasing over the past several decades, particularly in developed countries.
Who It Affects
Can occur at any age but most commonly diagnosed in people 20-30 years old. Risk factors include family history, smoking, and living in urban areas or northern climates. Ashkenazi Jewish descent carries higher risk.
Important: This information is for educational purposes only and does not constitute medical advice. Regenerative therapies are investigational and not FDA-approved to treat this condition.
Common Symptoms
Common Causes & Risk Factors
Traditional Treatment Options
Aminosalicylates
Anti-inflammatory drugs for mild to moderate Crohn's, primarily for colon involvement.
Limitations: Limited effectiveness in small intestine disease. May not be sufficient for moderate to severe disease.
Corticosteroids
Used to induce remission during flares.
Limitations: Not for maintenance therapy. Significant side effects with long-term use.
Immunomodulators
Medications like azathioprine or methotrexate to suppress immune response.
Limitations: Slow onset of action (3-6 months). Side effects include infections and rare lymphoma risk.
Biologic Therapies
TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors for moderate to severe disease.
Limitations: Expensive. Some patients don't respond or lose response over time. Infection risk.
Surgery
Removal of damaged intestinal segments; often needed eventually.
Limitations: Does not cure disease. Crohn's commonly recurs after surgery. Repeated surgeries risk short bowel syndrome.
Regenerative Medicine Approach
How Regenerative Therapy May Help
Regenerative medicine for Crohn's disease is being researched for potential immunomodulatory and tissue-healing effects. Mesenchymal stem cells have shown promise particularly for complex perianal fistulas, with one product approved in Europe. Research for luminal Crohn's is earlier stage.
Potential Benefits Being Studied:
- MSCs have shown promise for perianal fistulas
- Being studied for potential immunomodulatory effects
- May support intestinal tissue healing (under investigation)
- One MSC therapy approved in Europe for fistulas
- Research ongoing for luminal disease
- Does not replace standard IBD management
Biologics Used:
Mesenchymal stem cells (most studied for fistulas)
Exosomes being researched for anti-inflammatory effects
Frequently Asked Questions
Is stem cell therapy approved for Crohn's?
In Europe, one mesenchymal stem cell product (darvadstrocel/Alofisel) is approved specifically for complex perianal fistulas in Crohn's disease. This is not FDA-approved in the US. Other applications remain investigational.
Can this help my fistulas?
Perianal fistulas in Crohn's are the most studied application for MSC therapy. Some trials have shown promising healing rates. Discuss with your gastroenterologist whether this might be an option.
Should I stop my biologic medication?
No. Continue all prescribed medications unless directed otherwise by your gastroenterologist. Regenerative therapy research is generally being studied in addition to, not instead of, standard treatments.
Ready to Explore Your Options?
Schedule a free consultation to discuss crohn's disease and learn if regenerative medicine may be right for you.
Important Disclaimer
Regenerative therapies for Crohn's disease are investigational (except specific MSC therapy for fistulas approved in Europe, not US). IBD requires ongoing gastroenterology management. Never discontinue prescribed medications.